Date: 2013-06-11
Type of information:
phase:
Announcement: initiation
Company: Addenbrooke\'s Hospital (UK) Cambridge Institute for Medical Research (CIMR)
Product: aldesleukin
Action mechanism:
Disease: type 1 diabetes
Therapeutic area: Metabolic diseases
Country:
Trial details:
Latest
news: * On June 11, 2013, researchers at Addenbrooke\'s Hospital and the Wellcome Trust-funded Cambridge Institute for Medical Research (CIMR) at the University of Cambridge have announced that they are investigating whether interleukin-2 in the form of a drug called aldesleukin (Proleukin) could be used to halt the damage to the pancreas in people with newly diagnosed type 1 diabetes and, if so, what dose of the drug is required for the best results.The clinical trial is being led by Dr Frank Waldron-Lynch from the University of Cambridge and is coordinated by the Cambridge Clinical Trials Unit at Addenbrooke’s Hospital. The aim of the trial is to use aldesleukin to rebalance the immune system so that patients can significantly reduce the number of insulin injections needed to just once or twice a week by slowing the progression of the disease. The first two participants have been enrolled onto the trial and have received treatment. At the moment, the trial is to help gauge the necessary dose in adults, beginning with very low doses; ultimately, the researchers hope to be able to use this treatment in children.The trial is being funded by the Wellcome Trust and JDRF, the type 1 diabetes charity, combined with funding from the National Institute of Health Research, a UK government body that coordinates and funds research for the NHS.
